At Hyrax Biosciences, we believe in taking the complexity out of sequence data analysis. That's why our automated, cloud-based platform combines scalable tech and unique algorithms to deliver detailed and accurate genotype reports, eliminating the need for human intervention or the threat of human error.
The perks of our platformExatype is more than just a consolidated, streamlined platform that produces consistently accurate reporting.
It's also...
Drag and drop your sequence data to start analysis, and receive your report in any desired format.
With plug-ins for specific diseases – including HIV, TB and SARS-CoV-2 (Covid-19) – we are able to analyse data from an ever-expanding range of pathogens.
While we have software for quality control, mapping, mutation calling and interpretation, the Exatype pipeline can be tailored to suit your specific needs.
Being cloud-based, Exatype allows for a high-throughput of data and consistent report delivery, regardless of the number of jobs in the system at any given time.
Your data security means a lot to us. That's why we comply with all the necessary HIPAA regulatory requirements.
Next-generation sequencing reads are trimmed of low-quality bases, and short or otherwise inferior reads are discarded.
Examap, a novel, codon-aware reference mapping tool, uses an assembly-free approach to map sequence reads to one or more reference sequences while considering both sequencing error and true diversity.
Mutations are called in each individual read. The Examap algorithm allows mutations to be called with >99% per-read accuracy.
Relevant genes and mutations, at various prevalence levels, are reported and, if relevant, analysed using gold-standard drug-resistance testing algorithms.
Whether you're an assay or instrument manufacturer, a laboratory or service provider, a pharmaceutical or clinical trial organisation, or an academic or research institution, we can help you to offer an end-to-end DNA sequencing solution for an ever-growing range of pathogens.
From its origins in HIV drug-resistance testing, Hyrax has extended the Exatype genotyping platform to accommodate any disease or test. Our pipeline is currently being used to detect drug susceptibility in HIV, TB and cancer, as well as mutations, lineage and clade typing in SARS-CoV-2 (COVID-19).
SARS-COV-2 NGS
HIV NGS
HIV SANGER